InvestorsObserver
×
News Home

Is United Therapeutics Corporation (UTHR) Stock About to Get Hot Tuesday?

Tuesday, May 24, 2022 10:44 AM | InvestorsObserver Analysts

Mentioned in this article

Is United Therapeutics Corporation (UTHR) Stock About to Get Hot Tuesday?

Overall market sentiment has been high on United Therapeutics Corporation (UTHR) stock lately. UTHR receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
United Therapeutics Corporation has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on UTHR!

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With UTHR Stock Today?

United Therapeutics Corporation (UTHR) stock is up 2.79% while the S&P 500 has fallen -2.04% as of 10:34 AM on Tuesday, May 24. UTHR is up $5.86 from the previous closing price of $210.14 on volume of 152,525 shares. Over the past year the S&P 500 has fallen -7.26% while UTHR is up 14.52%. UTHR earned $14.44 a per share in the over the last 12 months, giving it a price-to-earnings ratio of 15.06. To screen for more stocks like United Therapeutics Corporation click here.

More About United Therapeutics Corporation

United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension. Click Here to get the full Stock Report for United Therapeutics Corporation stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App